We offer asset assessment and acquisition support by means of organized technical and regulatory due diligence. It starts with defining scope and evaluation objectives in accordance with investor or strategic acquisition goals. This is followed by systematic review of the data room materials which include the history of development, CMC documentation, clinical data, regulatory interactions, intellectual property, and quality systems.
Our team evaluates manufacturing preparedness, supply chain resilience, compliance, and regulatory risks. Formal gap analysis determines the gaps, liabilities, and remediation requirements. Long-term value is also determined by evaluating commercial positioning and lifecycle potential.
The results are presented in a concise due diligence report that identifies the risk grading, mitigation, and value-enhancement opportunities. Where necessary, HPC assists in the negotiation strategy by explaining the regulatory timelines and investment requirements. Integration planning after acquisition involves regulatory alignment, harmonization of documentation and refinement of development roadmap. This systematic approach allows the stakeholders to have an idea of the maturity of the assets, regulatory risk and growth prospects prior to investing.